Curiox Biosystems큐리옥스바이오시스템즈

Curiox Biosystems remains deeply loss-making, with its shares up sharply over three months despite a widening quarterly operating loss.

Curiox sells automated cell-washing instruments and consumables for life science, diagnostics and bio-pharma customers. On trailing twelve months to H1 2026 it had about ₩5.7B of revenue against an operating loss of about ₩13.0B, and it held ₩10.5B of cash with no borrowings. The share price is ₩62,300, up 62.5% over three months but down 10.5% over one year and well below its 52-week high of ₩149,200.

What stands out

• Trailing revenue of ₩5.7B is far below operating losses of ₩13.0B, giving an operating margin of -227.4%.
• Annual revenue rose 12.3% in 2025 to ₩5.2B, but the net loss widened to ₩27.2B that year.
• Cash of ₩10.5B exceeds borrowings of zero, though trailing free cash flow was negative at ₩9.3B.
• Valuation metrics are not meaningful on earnings: P/E is unavailable and price-to-book is 21.9x versus peers at about 3x to 6x.
• Foreign ownership fell from 9.4% to 5.7% over the past 60 days, while retail investors were net buyers over the last 20 days.

What to watch

• The preliminary consolidated earnings filing dated 2026-10-27 and news reports of a widening Q3 operating loss to ₩4B; the full filing details are not in the data.
• Further filings tied to stock purchase option grants and executive trading plans, which the data lists without detail.
• Whether the company can narrow losses and sustain its cash balance, given negative free cash flow and no profit history in the data provided.